amisulpride sandoz pharma amisulpride 100 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride sandoz pharma amisulpride 200 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride sandoz pharma amisulpride 400 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
sulprix amisulpride 200 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; lactose monohydrate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
sulprix amisulpride 100 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; hypromellose; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
sulprix amisulpride 400 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 400 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amipride 400 amisulpride 400 mg tablet blister pack
arrotex pharmaceuticals pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; methylcellulose; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; macrogol 600; basic butylated methacrylate copolymer - treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent.
amisulpride 200 winthrop amisulpride 200 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride 100 winthrop amisulpride 100 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; hypromellose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride 400 winthrop amisulpride 400 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; peg-40 stearate; lactose monohydrate; titanium dioxide; hypromellose; microcrystalline cellulose - the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.